On Sunday, U.S. President Donald Trump changed that precedent, announcing that he would sign an executive order Monday to ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...

The US FDA has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Cramer noted that investors are skirting Johnson & Johnson (NYSE:JNJ) because of worries regarding Robert Kennedy Jr., as he ...

The drug also showed a favorable safety profile, with adverse events comparable to placebo and no new safety signals observed. Liza O’Dowd, MD, of Johnson & Johnson, emphasized the potential of ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in ...

Johnson & Johnson recently experienced a 3% price increase in the last quarter, a period during which significant developments occurred for the company. Notably, the FDA granted approval for ...

“The sad truth is that the FDA ignored, enabled, or encouraged every Johnson & Johnson disaster in this book,” Gardiner writes. Even the good that the FDA is able to accomplish, he ...

Learn more about this approval in Johnson & Johnson’s news release ... and potentially life-changing treatment option. “FDA’s approval of IMAAVY TM (nipocalimab-aahu) is an important step ...